We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Allows Chantix Generics With High Levels of Nitrosamines

FDA Allows Chantix Generics With High Levels of Nitrosamines

July 21, 2021

The FDA said it will temporarily allow distribution of generics of Pfizer’s smoking cessation drug, Chantix (varenicline), even though they may contain more than the acceptable daily limit of a potential carcinogen — to ensure an adequate U.S. supply “for the near term.”

Pfizer suspended worldwide distribution of the drug last month after elevated levels of the suspected carcinogen, nitrosamine, were found in some batches of the pills.

The agency said it will “exercise regulatory flexibility and discretion” to allow Apotex — which currently distributes varenicline in Canada — to distribute its Apo-Varenicline tablets in the U.S.

The temporary approval covers tablets containing N-nitroso-varenicline above the agency’s acceptable intake limit of 37 nanograms per day but below the interim acceptable intake limit of 185 nanograms per day until the impurity “can be eliminated or reduced to acceptable levels.”

View today's stories

Pharmaceuticals Postmarket Safety

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 14Sep

    Omnichannel Engagement: Are You Digitally Ready?

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Organogenesis Gets 510(k) Clearance to Expand PuraPly Portfolio

  • FDA Grants Priority Review to sNDA for Lynparza

  • Visibly Gets 510(k) Clearance for Its Online Eye Test

  • Resilience Inks Collaboration Deal With Mayo Clinic Over Biotherapeutics

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing